Sandbox Reserved 1167

From Proteopedia

Class B Human Glucagon G-Protein Coupled Receptor

spinqualitylabelsall models Human Glucagon Class B GPCR ( 7tm PDB: 4l6r, ECD PDB: 4ers) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image Contents 1 Introduction 2 Function 3 Structure 3.1 Class B vs. Class A 3.2 GCGR-Specific Traits 3.2.1 Helix I Stalk Region Introduction Image:7tm labeled with membrane.png The 7tm spans the cell membrane The human glucagon receptor (GCGR) is one of 15 secretin-like, or Class B, G-protein coupled receptors (GPCRs). Like other GPCRs, it has a helical domain (shown in blue) and a globular N-terminus (shown in magenta). As its name suggests, the 7tm is made up of alpha helices that pass through the membrane seven times. The extracellular domain has an α-β-β structure that consists of two antiparallel β-sheets and a N-terminal α-helix[1]. Function The glucagon receptor plays an important role in glucose homeostasis. During times of fasting (or low blood sugar) the pancreas dispatches glucagon to activate the GCGR in the liver. The binding of glucagon stimulates gluconeogenesis, through adenylate cyclase that initiates protein kinase A (PKA) activity[2]. This pathway synthesizes glucose, elevating blood sugar levels. Structure Class B vs. Class A In contrast to class A glucagon receptors which have a proline kink, in all secretin-like class B glucagon receptors there is a Glycine at position 393 in Helix VII which allows for a . This glycine helical bend is fully conserved in all secretin-like class B receptors and is an important part of the FQGxxVxxYCF motif. Another important structural component found in all secretin-like class B receptors are the two conserved salt bridges found between Arg 346 and Glu 406 and Arg 173 and Glu 406 Glu 406 Salt Bridges . These salt bridges appear to be distinct feature of class B receptors only, however, because there is no conservation of these residues seen in class A receptors. A conserved disulfide bond can be found in 7tm region at which helps to stabilize the 7tm fold. This bond is conserved among both class A and class B receptors. Additionally, the ECD region of Class B GCPRs is defined by three conserved disulfide bonds. These bonds occur at , , and . As a part of the interface stabilization between helices VI, V, and III, a Class B-specific hydrogen bond occurs between Asn 318 of Helix V and Leu 242 of Helix III. Helical Interactions VI-V-III GCGR-Specific Traits Helix I Stalk Region The tip of Helix I extends above the cell membrane into the extracellular space creating a . This region is longer than any other class of GPCR and extends 3 α-helical turns above the plane of the membrane. It helps to capture the glucagon peptide and facilitates it's insertion into the 7tm[3]. By disrupting the normal interactions between the ECD and the 7tm domains, these antibiotics inhibit the receptor's function and help to lower blood glucose level. Additional research has shown that another antibody, mAb7, inhibits GCGR allosterically[4]. Through binding to a site outside of the binding pocket, mAb7 inhibits the receptor without interacting with essential glucagon binding residues.

References

1. ↑ Yang L, Yang D, de Graaf C, Moeller A, West GM, Dharmarajan V, Wang C, Siu FY, Song G, Reedtz-Runge S, Pascal BD, Wu B, Potter CS, Zhou H, Griffin PR, Carragher B, Yang H, Wang MW, Stevens RC, Jiang H. Conformational states of the full-length glucagon receptor. Nat Commun. 2015 Jul 31;6:7859. doi: 10.1038/ncomms8859. PMID:26227798 doi:http://dx.doi.org/10.1038/ncomms8859
2. ↑ Lotfy M, Kalasz H, Szalai G, Singh J, Adeghate E. Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus. Open Med Chem J. 2014 Dec 31;8:28-35. doi: 10.2174/1874104501408010028., eCollection 2014. PMID:25674162 doi:http://dx.doi.org/10.2174/1874104501408010028
3. ↑ PMID:23863937/ref>.

   Contents 1 Intracellular Helix VIII 2 Binding Pocket 3 Other Unique Structural Features 4 Glucagon Binding 5 Clinical Relevance

   Intracellular Helix VIII

   The GCGR also contains an intracellular Helix VIII that is comprised of roughly 20 amino acids at the C-terminal end. This helix tilts approximately 25 degrees away from the membrane - the corresponding position in class A receptors are turned toward the membrane<ref></ref>. Although researchers are not entirely sure of its function, this helix is completely conserved in class B structures.

   Binding Pocket

   The class B GPCR has the widest and longest binding pocket. The distance between the EC tips of Helicies II and VI as well as between the tips of Helicies III and VII are some of the largest among the GPCRs<ref></ref>. As a result, the binding cavity of GCGR is located deeper inside the molecule.

   Other Unique Structural Features

   An important interface stabilization interaction between Helices I and VII occurs between Ser 152 of Helix I and Ser 390 of Helix VII. Due to their close proximity to one another, they form an important which stabilizes the structure of GCGR.

   
   

   Glucagon Binding

   Research has shown that class B GCPRs exist in either an open or closed conformation. To transition between states, the ECD rotates and moves down towards the 7tm domain. The stalk region of Helix I helps to facilitate this motion of the ECD.

   In its open state, the ECD and the stalk region of Helix 1 are almost perpendicular to the membrane surface. In the case of GCGR, this open confirmation is stabilized by glucagon binding. In the absence of glucagon, however, the GCGR adopts a closed conformation in which all three of the extracellular loops of the 7tm (ECL1, ECL2, and ECL3) can interact with the ECD. In this closed state, the ECD covers the extracellular surface of the 7tm.

   This transition mechanism is consistent with the "two-domain" binding mechanism of class B GCPRs in which (1) the C-terminus of the ligand first binds to the ECD allowing (2) the N-terminus of the ligand to interact with the 7tm and activate the protein.​

   
   

   Clinical Relevance

   Because of GCGR's role in glucose homeostasis, it is a potential drug target for Type 2 diabetes. Specifically, molecules that antagonize the glucagon receptor may be able to lower blood sugar levels. Studies have shown that two antibodies, mAb1 and mAb23, target the ECD domain of the GCGR interrupting glucagon binding<ref>PMID:22908259</li>

   <li id="cite_note-3">[[#cite_ref-3|↑]] Mukund S, Shang Y, Clarke HJ, Madjidi A, Corn JE, Kates L, Kolumam G, Chiang V, Luis E, Murray J, Zhang Y, Hotzel I, Koth CM, Allan BB. Inhibitory mechanism of an allosteric antibody targeting the glucagon receptor. J Biol Chem. 2013 Nov 4. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/24189067 24189067] doi:[http://dx.doi.org/10.1074/jbc.M113.496984 http://dx.doi.org/10.1074/jbc.M113.496984]</li></ol></ref>